Should the approach translate to humans, people with allergies may one day be able to take a vaccine that protects them from ...

Click Therapeutics has collected a groundbreaking green light from the FDA for the agency’s first prescription digital ...

Precision Neuroscience has obtained an FDA clearance for a crucial piece of its plans for a full brain-computer interface ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. | Novartis has terminated a phase 2 trial evaluating an ...

The imaging provider RadNet aims to acquire iCad and its artificial intelligence-powered mammography software—with plans to ...